Biopolym. Cell. 2009; 25(1):50-55.
Viruses and Cell
Analysis of molecular features of the Ukrainian isolates of HIV-1
1Pukish N. S., 2Shcherbinska A. M., 2Babij N. O., 1Polishchuk V. P.
  1. Taras Shevchenko National University of Kyiv
    64, Volodymyrska Str., Kyiv, Ukraine, 01601
  2. Ukrainian Center for AIDS Prevention of the Ministry of Health of Ukraine
    5 Mykola Amosov str, Kyiv, Ukraine, 03038


Analysis of HIV-1 genome in the region of pol gene was performed by sequencing virus genome using 64 samples of blood from HIV-infected persons. Subtype a HIV-1 revealed to be dominating among investigated samples and a great number of samples belonged to a circulating recombinant forms of HIV-1. Analysis of mutations showed only one mutation connected with development of HIV-1 resistance to antiretroviral treatment. Most samples included polymorphic substitutions of nucleotides in the virus genome region studied.
Keywords: human immunodeficiency virus 1, polymorphic substitutions, resistance mutations, recombinant forms of HIV-1, subtype of HIV-1


[1] Gallo R. C., MontagnierL. The discovery of HIV as the cause of AIDS New Engl. J. Med 2003 349, N 24:2283– 2285.
[2] UNAIDS. AIDS Epidemic Update: December 2007.
[3] Requejo H. Worldwide molecular epidemiology of HIV Rev. Saude Publica 2006 40, N 2:331–345.
[4] Peters M., Sharp R. M. Genetic diversity of HIV-1: the moving target. AIDS. 2000; 14(3):129–140.
[5] McCutchan F. E. Understanding the genetic diversity of HIV1. AIDS. 2000; 14(3):31–44.
[6] Barlet J., Galant J. Clinical aspects of HIV-infection M.: EnRus, 2007 557 p.
[7] de Ronde A., van Dooren M., van der Hoek L., Bouwhuis D., de Rooij E., van Gemen B., de Boer R., Goudsmit J. Esteblishment of new transmissible and drug sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus J. Virol 2001 75:595–602.
[8] Clavel F., Hance A. HIV drug resistance New Engl. J. Med 2004 350, N 10:1023–1035.
[9] Vijver D., Wensing A., Boucher C. The epidemiology of transmission of drug resistant HIV-1. Sequence compendium 2006/2007 Los Alamos, 2007:17–36.
[10] Tatt I., Barlow K., Nicoll A., Clewley J. The public health significance of HIV-1 subtypes. AIDS. 2001; 15, N 24 P. 59–71.
[11] Saad M., Shcherbinskaya A., Nadai Y., Kruglov Y., Antonenko S., Lyullchuk M., Kravchenko O., Earhart K., Sanchez J., Birx D., Carr J. Molecular epidemiology of HIV type 1 in Ukraine: birthplace of an epidemic AIDS Res. and Hum. Retroviruses 2006 22, N 8:709–714.
[12] Nabatov A., Kravchenko O., Lyulchuk M., Shcherbinskaya A., Lukashov V. Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug users in southern Ukraine at the beginning of the epidemic in the former Soviet Union AIDS Res. and Hum. Retroviruses 2002 18, N 12:891–895.
[13] Johnson V., Vezinet F., Clotet B., Gunthart H., Kuritzkes D., Pillay D., Shapiro J., Richman D. Update of drug resistance mutations in HIV-1: 2007 Top. HIV Med. 2007; 15(4):119–125.
[14] Johnson V., Brun-Vezinet F., Cloet B., Gunthart H., Kuritzkes D., Pillay D., Shapiro J., Richman D. Update of Drug Resistance Mutations in HIV-1: 2006. Top. HIV Med. 2006; 14(3):125–130.
[15] Shafer R., Rhee S., Pillay D., Miller V., Sandstrom P., Shapiro J., Kuritzkes D., Bennet D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance AIDS 2007 21:215–223.
[16] HIV drug resistance mutations by drug class (January 28, 2008) –
[17] Sukasem C., Churdboonchart V., Sukeepaisarncharoen W., Piroj W., Inwisai T., Tiensuwan M., Chantratita W. Genotypic resistance profiles in antiretroviral-naVve HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy Int. J. Antimicrob. Agents 2008 31, N 3:277–281.
[18] Hu D., Subbarao S., Vanichseni S., Mock P., Ramos A., Nguyen L., Chaowanachan T., Griensven F., Choopanya K., Mastro T., Tappero J. Frequency of HIV-1 dual subtype infections, including intersubtype infections, among injection drug users in Bangkok, Thailand. AIDS. 2005;19(3):303-8.